A Real-World Observational Study Evaluating the Probability of Glycemic Control with Basal Insulin or Glucagon-Like Peptide-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes

Mike Baxter · Yukiko Morimoto · Masami Tamiwa · Masakatsu Hattori · Xuejun Victor Peng · Robert Lubwama · Hiroshi Maegawa

Received: March 17, 2020 / Published online: May 22, 2020 © The Author(s) 2020

ABSTRACT

Introduction: The effectiveness of basal insulin (BI) or glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in providing glycemic control in patients with type 2 diabetes (T2D) in Japanese routine practice is not well known. This real-world observational study evaluated the probability of achieving glycemic control in Japanese patients with T2D uncontrolled by oral antidiabetic drugs (OADs) who initiated BI or GLP-1 RA therapy.

Methods: Patients with T2D aged ≥ 18 years initiating BI or GLP-1 RA therapy following treatment with OADs were selected from real-world data (RWD) retrieved from a large electronic medical record database in Japan, using data from 01 January 2010 to 30 June 2019. Patients were required to have glycated hemoglobin (HbA1c) ≥ 7% within 90 days prior to the first prescription of BI or GLP-1 RA. The probability of reaching first HbA1c < 7% was assessed over a 24-month period in cohorts of patients who initiated BI (n = 3477) or GLP-1 RA (n = 780) and in subcohorts by number of OADs at baseline (1, 2, or ≥ 3), HbA1c at baseline (≥ 7 to < 8%, ≥ 8 to < 9%, or ≥ 9%), and age (< 65 or ≥ 65 years).

Results: Mean (standard deviation) baseline HbA1c was 9.4% (1.8%) and 8.8% (1.4%) in patients initiating BI or GLP-1 RA therapy, respectively.
respectively. The cumulative probability of achieving glycemic control was 50.1% with BI and 60.3% with GLP-1 RA therapy, respectively, at 12 months, and 60.8% and 66.6%, respectively, at 24 months. Quarterly (3-month intervals) conditional probabilities of achieving glycemic control decreased over time and were <10% after 12 months. Patients with more OADs or higher HbA1c at baseline had a lower probability of achieving glycemic control.

**Conclusion:** Among Japanese patients with T2D who initiated BI or GLP-1 RA therapy after treatment with OADs, the probability of reaching first glycemic control diminished over time. Further therapy intensification is warranted in patients who do not achieve glycemic control within 6–12 months with BI or GLP-1 RA, particularly those with high HbA1c or taking multiple OADs.

**PLAIN LANGUAGE SUMMARY**

Patients with type 2 diabetes (T2D) who are taking oral antidiabetic drugs (OADs) but still have high blood glucose often require injectable drugs, such as basal insulin (BI) or glucagon-like peptide-1 receptor agonists (GLP-1 RAs). While BI and GLP-1 RAs have been shown to be effective in controlled clinical trials, it is unclear how well they improve blood glucose in real-world routine practice. Here, we report the results of an observational study that used data retrieved from a large electronic medical records database in Japan to explore how well BI and GLP-1 RAs allow patients to achieve glycemic control [glycated hemoglobin (HbA1c) < 7%].

In Japanese patients with T2D receiving treatment with OADs and initiating BI or GLP-1 RA therapy, the probability of achieving glycemic control in the first quarter (3 months) after initiation was 20.3% with BI and 38.6% with GLP-1 RA. Among those patients who had not previously reached glycemic control, the probability of achieving first glycemic control declined over time, as evidenced in each quarterly assessment, and it was <10% after the first year. Patients who had higher HbA1c levels or were taking multiple OADs were less likely to achieve glycemic control compared with those with lower HbA1c or taking fewer OADs. Our findings suggest that patients who have not achieved their glycemic goals within the first 6–12 months after starting BI or GLP-1 RA therapy have a low likelihood of achieving their target by maintaining the same therapy. For such patients, intensification with additional medication (e.g., combined BI and GLP-1 RA therapy) should be considered early in treatment.

**Keywords:** Basal insulin; GLP-1 RA; Real-world evidence; Type 2 diabetes

| Key Summary Points |
|--------------------|
| **Why carry out this study?** |
| Although basal insulin (BI) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated efficacy in randomized controlled trials, it remains unclear whether these agents, when used individually, are sufficient to provide glycemic control in patients with type 2 diabetes (T2D) in real-world practice. |
| Real-world evidence from patients with T2D in the USA and UK suggests that patients not achieving glycemic targets within 6–12 months following initiation of BI or GLP-1 RA therapy may benefit from treatment intensification (options include combined BI and GLP-1 RA and basal-bolus regimens); however, the relevance of these data to Japanese patients is unknown. |
| This real-world observational study was conducted to evaluate the probability of achieving glycemic control in Japanese patients with T2D uncontrolled on oral antidiabetic drugs (OADs) alone who initiate BI or GLP-1 RA therapy. |
What was learned from the study?

In Japanese patients with T2D uncontrolled on OADs alone, the conditional probability (percentage of patients who achieved glycemic control among those who had not previously reached glycemic control) of reaching first glycated hemoglobin (HbA1c) < 7% was 20.3% with BI and 38.6% with GLP-1 RA therapy in the first quarter (3-month interval) after BI or GLP-1 RA initiation; the conditional probability in each subsequent quarter declined over time, and it was < 10% for both treatments after the first year. Throughout the 2-year follow-up period, subgroups of patients who initiated BI or GLP-1 RA therapy with HbA1c ≥ 9% or who were taking ≥ 3 OADs had a lower probability of achieving glycemic control compared with those with lower baseline HbA1c or fewer OADs.

Treatment intensification should be considered for patients who have not achieved glycemic goals within the first 6–12 months of initiating BI or GLP-1 RA treatment.

Patients taking BI or GLP-1 RA therapy who have higher baseline HbA1c or who are taking multiple OADs are less likely to be successful in achieving adequate glycemic control after intensification with single injectable therapy.

There is a need for different intensification strategies for those patients who are taking multiple OADs or have high baseline HbA1c.

INTRODUCTION

Type 2 diabetes (T2D) is a chronic disease characterized by insulin resistance and progressive decline in β-cell function and insulin secretion, resulting in hyperglycemia [1, 2]. Persistent hyperglycemia is associated with an increased risk of microvascular complications, such as neuropathy, retinopathy, and nephropathy; therefore, attaining ongoing glycemic control is critical to T2D management [3, 4]. In standard clinical practice, glycemic control is assessed using glycated hemoglobin (HbA1c) levels, and HbA1c < 7% has become an accepted therapeutic target based on the reduced risk of diabetic complications in patients achieving this target [5–7].

Current guidelines, including those set forth by the American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD), and Japan Diabetes Society (JDS), recommend stepwise treatment approaches to help patients achieve and maintain glycemic control [5, 6]. In patients whose glycemic levels are inadequately controlled on oral antidiabetic drugs (OADs), escalation to injectable therapy is required. Current JDS guidelines recommend that initial injectable therapies should focus on basal insulin (BI) or glucagon-like peptide-1 receptor agonists (GLP-1 RAs). In the 2018 ADA/EASD consensus report, GLP-1 RAs are recommended as the first injectable for managing T2D for most patients [5]. Combination therapy with both BI and GLP-1 RAs is an option for patients who do not achieve glycemic control on either agent alone [5, 6].

The efficacy and safety of BI and GLP-1 RAs have been well established in randomized controlled trials (RCTs) [8–11]; however, in real-world practice, monotherapy with either agent may be insufficient to provide glycemic control in many patients with T2D. A retrospective, observational study found that among patients in the USA initiating BI therapy following OADs, the cumulative probability of reaching glycemic control (HbA1c < 7%) was 38% in the first year and only increased by a further 8% in the second year [12]. Similar trends were observed in a UK-based retrospective database study of patients initiating BI or GLP-1 RA therapy, with the cumulative probability of reaching HbA1c < 7% within 12 months being 18% with BI and 30% with GLP-1 RA therapy, with a low rate of increase over the second year (11% and 12%, respectively) [13]. These studies
suggest that intensification should be considered for patients not achieving glycemic control within 6–12 months of BI or GLP-1 RA initiation, and highlight the need for treatment approaches that allow more patients to achieve glycemic goals [12, 13]. However, it is not known whether lessons from these data are applicable outside of the USA or UK.

Here, we report the results of our real-world observational study, which evaluated the probability of achieving glycemic control in Japanese patients with T2D uncontrolled by oral antidiabetic drugs (OADs) who initiated BI or GLP-1 RA therapy, using data retrieved from a large electronic medical record (EMR) database in Japan. We also investigated the association between glycemic control and patient baseline characteristics, including number of OADs and baseline HbA1c.

METHODS

Study Design and Cohort Construction

This was a population-based, retrospective, observational cohort study using the RWD database maintained by the Health, Clinic, and Education Information Evaluation Institute (HCEI; Kyoto, Japan) with support from Real World Data, Co., Ltd. (Kyoto, Japan). The HCEI authorized the use of data for the current study. This database has collected EMRs of about 20 million patients from approximately 160 medical institutions across Japan since 2000, and includes information on patient demographics, diagnoses, prescriptions, procedures, and laboratory results from both outpatient and inpatient services. Data were automatically extracted from EMRs at each medical institution and anonymized using unique identifiers for each patient.

Data in the EMRs from 01 January 2010 to 30 June 2019 were used for this analysis. Patients were included in the study cohort if they had a confirmed diagnosis of T2D and had initiated BI or GLP-1 RA therapy following treatment with OADs. The date of first prescription of BI or GLP-1 RA was defined as the index date. Full inclusion criteria were: (1) diagnosis of T2D identified using ICD-10 [10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD)] codes; (2) at least one prescription for an OAD before initiation of BI or GLP-1 RA therapy; (3) at least one prescription of BI or GLP-1 RA; (4) intensification from OAD to BI or GLP-1 RA (first antidiabetic medication was not a BI or GLP-1 RA); (5) at least one HbA1c measurement ≥ 7% within 90 days prior to and including the index date; (6) at least one HbA1c measurement within 720 days after the initiation date of BI or GLP-1 RA therapy; (7) at least 180 days of recorded medical history prior to the index date (baseline period), during which no insulin or GLP-1 RA was prescribed; (8) age ≥ 18 years on the index date; and (9) study entrance at least 720 days prior to the data cutoff date to ensure up to 720 days of follow-up. Exclusion criteria were: (1) ICD-10/Japanese disease codes for type 1 diabetes, gestational diabetes, or polycystic ovarian syndrome; (2) an index date and end date (last date of BI or GLP-1 RA prescription) within 30 days; and (3) initiation of BI and GLP-1 RA therapies on the same date (same index date) or the addition of one medication within 3 months of the index date of the other medication (i.e., initiated BI and added a GLP-1 RA within 3 months of initiation of BI, or vice versa).

The patient selection process was designed based on the original objective of the study, which was to assess glycemic control in patients who initiated BI or GLP-1 RA (without sequential therapy with the other agent) and in those who received sequential therapy with BI and GLP-1 RA (added BI to GLP-1 RA, or vice versa). As the number of patients with records of sequential therapy was low, the cohorts of patients with sequential therapy were excluded from the present analyses. Therefore, the main study cohorts in this study consisted of patients who initiated BI or GLP-1 RA, without sequential therapy.

Within the study cohorts of patients initiating BI or GLP-1 RA (without sequential therapy), subcohorts of patients were constructed based on: (1) the number of OADs taken at baseline (1, 2, or ≥ 3 OADs); (2) the last HbA1c value prior to and up to the BI or GLP-1 RA initiation date (7 to < 8%, 8 to < 9%, and
baseline characteristics and glycemic outcomes were analyzed in the cohorts of patients initiating BI or GLP-1 RA (without sequential therapy). Glycemic control was determined by change in HbA1c over time and cumulative probability of reaching glycemic control (HbA1c < 7%) over 720 days post index date. Other outcome measures included the time to first reaching glycemic control and the conditional probability of reaching glycemic control during each quarter (3-month interval) post index date.

The cumulative probability of reaching glycemic control was also analyzed in the subcohorts of patients stratified by number of OADs used at baseline, HbA1c at baseline, and age on index date.

Outcome Measures

Baseline characteristics and change in HbA1c over time from baseline were analyzed using descriptive statistics. The period used to collect baseline characteristics was over 180 days prior to and up to the index date. The baseline HbA1c value was defined as the last observation within 90 days prior to and including the index date.

The conditional probability of reaching glycemic control was estimated quarterly (3-month intervals post index date) as the proportion of patients reaching first HbA1c < 7% within the specific quarter, among those patients who had not previously achieved glycemic control and were still taking BI or GLP-1 RA therapy and who had at least one valid HbA1c measurement in that quarter. The cumulative probability of reaching first glycemic control over time was estimated using the Kaplan–Meier method, and log-rank tests were used for comparison between subcohort categories. A P value of < 0.05 was considered to indicate statistical significance.

Patient data were censored at the end of BI or GLP-1 RA prescription, or when the patient was switched to a new non-BI or non-GLP-1 RA regimen or other insulin therapy. Records of HbA1c < 4% or > 15% were removed.

RESULTS

Patient Cohort Selection

A total of 4356 patients initiating BI or GLP-1 RA therapy following OAD treatment were identified from the EMR database (Fig. 1). Among these patients, 58 and 41 patients, respectively, had records of sequential therapy with BI followed by GLP-1 RA add-on, or GLP-1 RA followed by BI add-on, and were excluded from the analysis. The final analysis cohorts included 3477 patients who initiated BI and did not receive sequential therapy with GLP-1 RA (BI cohort), and 780 patients who initiated GLP-1 RA and did not receive sequential therapy with BI (GLP-1 RA cohort).

Median and range of follow-up time (time between index date and end date of BI or GLP-1 RA prescription) for the study cohorts and subcohorts are shown in Table 1 and Electronic Supplementary Material (ESM) Tables S1 and S2.

Baseline Characteristics

Patient demographics and baseline clinical characteristics of all the study cohorts (whole T2D, BI, and GLP-1 RA) are described in Table 1. BIs and GLP-1 RAs identified in the study are listed in ESM Table S3.

Patients initiating therapy with GLP-1 RA were younger than those initiating BI therapy (median age: 60.5 vs. 65.4 years, respectively). Patients who initiated BI had higher baseline HbA1c than those who initiated GLP-1 RA [mean (standard deviation, SD): 9.4% (1.8%) vs. 8.8% (1.4%), respectively]. Patients in the GLP-1
RA cohort appeared to have a higher body mass index (BMI) than those in the BI cohorts (mean: 28.2 vs. 24.1 kg/m², respectively). Regarding common comorbidities, hypertension, dyslipidemia, and obesity were more common in the GLP-1 RA cohort than in the BI cohort (hypertension: 73.2 vs. 63.9%, respectively; dyslipidemia: 77.3 vs. 65.2%, respectively; obesity: 14.2 vs. 4.2%, respectively). Over one third of patients in the BI and GLP-1 RA cohorts were taking ≥ 3 OADs. Higher percentages of patients in the BI cohort compared with the GLP-1 RA cohort were taking sulfonylureas (62.2 vs. 54.9%, respectively) or alpha-glucosidase inhibitors (34.7 vs. 24.2%, respectively). A higher percentage of patients in the GLP-1 RA cohort versus the BI cohort were taking metformin (56.3 vs. 38.9%, respectively), a dipeptidyl peptidase-4 (DPP-4) inhibitor (63.6 vs. 48.9%, respectively), or a sodium-glucose cotransporter 2 inhibitor (8.5 vs. 1.2%, respectively). Additional details on patient demographics and baseline clinical characteristics in patient subcohorts by number of OADs (1, 2, or ≥ 3) and
Table 1 Baseline characteristics and follow-up time for the whole T2D, BI, and GLP-1 RA cohorts

|                              | Whole T2D cohort  | BI cohort   | GLP-1 RA cohort |
|------------------------------|-------------------|-------------|-----------------|
|                              | \( n = 272,813 \) | \( n = 3,477 \) | \( n = 780 \)   |
| Age                          |                   |             |                 |
| Mean (SD)                    | 69.9 (13.8)       | 64.3 (12.4) | 59.7 (13.5)     |
| Median                       | 72.2              | 65.4        | 60.5            |
| ≥ 65 years, \( n \) (%)      | 196,152 (71.9)    | 1782 (51.3) | 287 (36.8)      |
| Female, \( n \) (%)          | 120,477 (44.2)    | 1,316 (37.8)| 345 (44.2)      |
| HbA1c, %                     |                   |             |                 |
| Mean (SD)                    | 6.5 (1.1)         | 9.4 (1.8)   | 8.8 (1.4)       |
| Median (range)               | 6.0 (2.4–6.9)     | 9.1 (7.0–20.2) | 8.5 (7.0–15.8) |
| HbA1c category               |                   |             |                 |
| 7–< 8%, \( n \)              | 21,055            | 745         | 253             |
| Median (range)               | 7.3 (7.0–7.9)     | 7.4 (7.0–7.9) | 7.5 (7.0–7.9)  |
| 8–< 9%, \( n \)              | 6758              | 888         | 241             |
| Median (range)               | 8.3 (8.0–8.9)     | 8.4 (8.0–8.9) | 8.4 (8.0–8.9)  |
| ≥ 9%, \( n \)                | 4357              | 1844        | 286             |
| Median (range)               | 9.8 (9.0–18.7)    | 10.4 (9.0–20.2) | 10.0 (9.0–15.8) |
| Mean (SD) BMI\(^a\), kg/m\(^2\) | 23.4 (4.5)       | 24.1 (4.2)  | 28.2 (5.8)      |
| Mean (SD) T2D duration, years | 7.3 (6.1)       | 6.5 (6.3)   | 6.5 (5.9)       |
| Follow-up time\(^c\), days (Q1–Q3) | NA              | 720 (622–720) | 720 (627–720) |
| Comorbidity\(^d\), \( n \) (%) |                   |             |                 |
| Hypertension                 | 14,397 (5.3)     | 2223 (63.9) | 571 (73.2)      |
| Dyslipidemia                 | 10,977 (4.0)     | 2268 (65.2) | 603 (77.3)      |
| Obesity                      | 2467 (0.9)       | 146 (4.2)   | 111 (14.2)      |
| Renal impairment             | 4896 (1.8)       | 391 (11.2)  | 105 (13.5)      |
| Atherosclerotic cardiovascular disease | 25,167 (9.2) | 1903 (54.7) | 421 (54.0) |
| Number of OADs, \( n \) (%)  |                   |             |                 |
| 1                            | 216,636 (79.4)   | 1114 (32.0) | 194 (24.9)      |
| 2                            | 25,329 (9.3)     | 1127 (32.4) | 250 (32.1)      |
| ≥ 3                          | 17,698 (6.5)     | 1236 (35.5) | 336 (43.1)      |
| Prescription of OAD, \( n \) (%) |                   |             |                 |
| Metformin                    | 22,468 (8.2)     | 1352 (38.9) | 439 (56.3)      |
| Sulfonylureas                | 13,031 (4.8)     | 2164 (62.2) | 428 (54.9)      |
| DPP-4 inhibitors             | 41,647 (15.3)    | 1701 (48.9) | 496 (63.6)      |

\(^a\) BMI = Body Mass Index
\(^b\) Metformin
\(^c\) Sulfonylureas
\(^d\) DPP-4 inhibitors
\(^e\) Outcomes
baseline HbA1c (7 to <8%, 8 to <9%, or ≥9%) within the BI and GLP-1 RA cohorts are shown in ESM Tables S2 and S3.

**HbA1c Change Over Time**

Distributions of HbA1c values from 6 months before to 24 months after initiation of BI or GLP-1 RA therapy are shown in Fig. 2. For both cohorts, mean HbA1c levels tended to be higher during the 3 months prior to the index date, followed by a rapid decrease within 2–4 months post index date, without further improvement thereafter.

HbA1c change from baseline by quarter (3-month time intervals) after the initiation of BI or GLP-1 RA therapy are shown in ESM Table S4. For both cohorts, mean (SD) HbA1c reduction from baseline peaked at 3–6 months following initiation, at −1.85% (2.03%) for BI and −1.26% (1.64%) for GLP-1 RA.

**Cumulative Probability of Patients Achieving Glycemic Control**

The Kaplan–Meier curves for the cumulative probability of patients reaching their first HbA1c <7% over time showed similar trends in the BI and GLP-1 RA cohorts (Fig. 3a, b), with a sharp increase in probability within 6 months following the initiation of BI or GLP-1 RA therapy and only a slight increase thereafter. In the BI cohort, approximately 28.6, 40.7, 50.1, and 60.3% of patients achieved their first HbA1c <7% within 3, 6, 12, and 24 months, respectively; these proportions were 39.5, 50.9, 60.8, and 66.6%, respectively, in the GLP-1 RA cohort.

In both the BI and GLP-1 RA cohorts, patients taking greater numbers of OADs at baseline showed a lower cumulative probability of achieving glycemic control throughout the 24-month follow-up period (Fig. 3c, d). For both the BI and GLP-1 RA cohorts, differences between subcohorts by number of OADs at baseline were significant according to log-rank test (P < 0.05 for all pair-wise comparisons between subcohorts). In both cohorts, the subcohorts of patients with baseline HbA1c ≥9% had the lowest cumulative probability of achieving glycemic control, while those with HbA1c 7–<8% had the highest probability (Fig. 3e, f); all pair-wise comparisons between subcohorts showed significant differences (P < 0.01) by the log-rank test.

### Table 1 continued

|                      | Whole T2D cohort n = 272,813 | BI cohort n = 3,477 | GLP-1 RA cohort n = 780 |
|----------------------|-----------------------------|--------------------|------------------------|
| TZDs                 | 4811 (1.8)                  | 650 (18.7)         | 129 (16.5)             |
| SGLT-2 inhibitors    | 6866 (2.5)                  | 42 (1.2)           | 66 (8.5)               |
| Alpha-GI             | 10,746 (3.9)                | 1205 (34.7)        | 189 (24.2)             |
| Glinide              | 4936 (1.8)                  | 351 (10.1)         | 71 (9.1)               |

*Alpha-GI* alpha-glucosidase inhibitor, *BI* basal insulin, *BMI* body mass index, *DPP-4* dipeptidyl peptidase-4, *GLP-1 RA* glucagon-like peptide-1 receptor agonist, *HbA1c* glycated hemoglobin, *ICD* International Classification of Diseases, *NA* not applicable, *OAD* oral antidiabetic drug, *Q1* lower quartile, *Q3* upper quartile, *SD* standard deviation, *SGLT-2* sodium-glucose cotransporter 2, *T2D* type 2 diabetes, *TZD* thiazolidinedione

a Data are for HbA1c <7%
b n = 589 (BI cohort) and 120 (GLP-1 RA cohort). BMI is available for inpatients only
c Follow-up time for probability of glycemic control analyses (index date to last date of BI or GLP-1 RA prescription)
d Obesity was defined as a BMI ≥30 kg/m² or the presence of ICD-10 codes for obese/morbidly obese; the other comorbidities were based on ICD-10 codes
notable differences were observed in the cumulative probability curves between subcohorts by age (≤ 65 or ≥ 65 years) in either the BI or the GLP-1 RA cohorts (data not shown).

Estimation of Conditional Probabilities

The proportion of patients who reached their first HbA1c < 7% within the first quarter (0–3 months post index date) was 20.3% in the BI cohort and 38.6% in the GLP-1 RA cohort (Table 2). Among patients who had not reached HbA1c < 7% in the first quarter following the index date, the probability of reaching first glycemic control in the second quarter was 17.3% for the BI cohort and 19.0% for the GLP-1 RA cohort (Table 2). The respective conditional probabilities declined to 8.9% and 9.4% in the third quarter, and remained at < 10% thereafter for both cohorts (other than a 12.9% probability in the fourth quarter for GLP-1 RA).

DISCUSSION

Based on data in the Japanese RWD database between January 2010 and June 2019, approximately fourfold more patients intensified their OAD therapy with BI compared with GLP-1 RA.
Initiation of BI or GLP-1 RA therapy occurred at an advanced stage of disease, after a mean of 6.5 years with T2D and high HbA1c [mean HbA1c of 9.4% (BI) and 8.8% (GLP-1 RA)], with over one third of patients taking ≥ 3 OADs. The delay in treatment intensification, or clinical

Fig. 3 Overall cumulative probability of reaching first HbA1c < 7% within 2 years post index date in the BI cohort (a) and GLP-1 RA cohort (b), and in subcohorts by number of OADs among the BI cohort (c) or GLP-1 RA cohort (d) or by HbA1c at baseline among the BI cohort (e) or GLP-1 RA cohort (f).
inertia, observed in the present study is consistent with previous real-world studies in Japan, which found that the mean HbA1c of patients initiating BI therapy was 9.4% [15, 16]. Similarly, in the DAWN JAPAN survey study, the mean HbA1c at which insulin therapy was recommended by physicians was 9.6% [17].

Patients initiating GLP-1 RA therapy tended to be younger than those initiating BI therapy, with a lower mean baseline HbA1c. In addition, consistent with the benefits of body weight associated with the GLP-1 RA class, patients initiating GLP-1 RA therapy had a higher BMI at baseline than those initiating BI. Observed differences in the types of OADs used may reflect differences in disease pathophysiology between patients initiating BI versus GLP-1 RA therapies. The use of sulfonylureas, which are insulin secretagogues suited for patients with insulin deficiency, was higher in patients initiating BI than in those initiating GLP-1 RAs, while metformin, which reduces blood glucose at least in part by improving insulin sensitivity, was used more frequently in patients initiating GLP-1 RAs compared with those initiating BI. The use of alpha-glucosidase inhibitors, which delay the absorption of sugars by inhibiting enzymes, thereby reducing postprandial hyperglycemia, was more common among patients initiating BI than in those initiating GLP-1 RA therapy. DPP-4 inhibitors, which block the degradation of endogenous GLP-1 and promote glucose-dependent insulin secretion, were also more commonly used by patients initiating GLP-1 RA therapy. However, it is worth noting that about half of the patients initiating BI therapy were also being treated with DPP-4 inhibitors, in line

Table 2: Conditional probability of reaching first glycemic control (HbA1c < 7%)

| Time after initiation of BI or GLP-1 RA therapy (months) | BI cohort | GLP-1 RA cohort |
|---------------------------------------------------------|-----------|----------------|
|                                                          | Number of patients who had not reached glycemic control previously and were still on treatment and had at least one valid HbA1c record within this quarter | Number of patients who reached their first glycemic control within this quarter |
|                                                          | Estimated conditional probabilitya, % (95% CI) | Estimated conditional probabilitya, % (95% CI) |
| > 0–3                                                   | 3320 | 674 | 20.3 (18.9–21.7) | 762 | 294 | 38.6 (35.1–42.0) |
| > 3–6                                                   | 1453 | 251 | 17.3 (15.3–19.2) | 406 | 77 | 19.0 (15.2–22.8) |
| > 6–9                                                   | 1087 | 97 | 8.9 (7.2–10.6) | 299 | 28 | 9.4 (6.1–12.7) |
| > 9–12                                                  | 886 | 72 | 8.1 (6.3–9.9) | 249 | 32 | 12.9 (8.7–17.0) |
| > 12–15                                                 | 751 | 52 | 6.9 (5.1–8.7) | 205 | 13 | 6.3 (3.0–9.7) |
| > 15–18                                                 | 647 | 34 | 5.3 (3.5–7.0) | 177 | 6 | 3.4 (0.7–6.1) |
| > 18–21                                                 | 584 | 36 | 6.2 (4.2–8.1) | 160 | 6 | 3.8 (0.8–6.7) |
| > 21–24                                                 | 510 | 26 | 5.1 (3.2–7.0) | 144 | 5 | 3.5 (0.5–6.5) |

CI Confidence interval

a Conditional probability is defined as the percentage of patients achieving glycemic control within the specified time interval, among patients who had not reached glycemic control previously, were still on treatment, and had at least one valid HbA1c record within the time interval.
with the prevalent use of this class of drugs in
Japanese patients with T2D [18].

In patients initiating BI or GLP-1 RA therapy, HbA1c levels tended to increase rapidly during the 3 months prior to initiation, which may have prompted the initiation of injectable therapy. This trend was then followed by a rapid decrease within 2–4 months of treatment initiation, without further improvement thereafter. Although there was a sharp increase in the cumulative probability of reaching HbA1c < 7% within 6 months of initiation of BI or GLP-1 RA therapy, the rates of increase declined over time. The conditional probability of achieving HbA1c < 7% with BI or GLP-1 RA therapy was highest in the first 3 months following treatment initiation (20.3% for BI and 38.6% for GLP-1 RA), then declined thereafter to < 10% after 6–12 months. These data are consistent with the findings from similar retrospective database studies in the UK [13] and USA [12] and suggest that for Japanese patients who have not reached glycemic goals at early stages of BI or GLP-1 RA treatment, the probability of achieving the target is low, and early treatment escalation is warranted. Reports of factors that might adversely influence the prescribing of GLP-1 RAs in Japan appear to be limited. However, it is possible that the injectable nature of the treatment is a limitation. Furthermore, one of the perceived advantages of GLP-1 RAs in Western countries (namely, weight loss) is not a major clinical objective in Japanese patients with T2D.

Patients initiating BI or GLP-1 RA therapy with higher baseline HbA1c or those who were taking multiple OADs had a lower probability of achieving HbA1c < 7% throughout the 2-year follow-up period compared with those with lower baseline HbA1c or taking fewer OADs. In line with the approach of early intensive therapy in patients with high HbA1c, the 2018 ADA/EASD consensus report recommends initial injectable combination therapy with GLP-1 RA and BI or prandial/BI for patients with HbA1c > 10% and/or > 2% above target [5]. However, while insulin in combination with a GLP-1 RA is listed as a treatment option for patients with inadequate glycemic control, the current JDS guidelines do not make a recommendation for any specific combination to be used as initial injectable therapy [6].

The importance of glycemic control in lowering the risk of diabetes complications is highlighted in the ADA, EASD, and JDS guidelines, and the benefits of aggressive glycemic management have been shown by long-term studies. The UK Prospective Diabetes Study demonstrated over 10 years of follow-up that intensive blood-glucose control substantially decreases the risk of microvascular complications in patients with T2D [4]. In a prospective study in Japan, intensive glycemic control was associated with a delay in the onset and progression of diabetic retinopathy, nephropathy, and neuropathy in patients with T2D [3].

The efficacy and safety of BI and GLP-1 RA therapies in Japanese patients are well established in RCTs [19–26]. While RCTs provide a controlled setting to evaluate the effects of therapeutic interventions using standardized treatments in a well-defined patient cohort, they may not necessarily fully reflect the treatment practices and patient populations seen in real-world practice. Indeed, there is a gap between the efficacy of glycemia-lowering agents reported from RCTs and that reported from real-world studies, with smaller improvements in HbA1c observed in the real world [27]. Real-world data may guide individualized treatment decisions and provide important insights into the challenges that are encountered in routine clinical practice. In our current real-world database study, initiation of BI or GLP-1 RA therapy was insufficient to provide HbA1c control for many Japanese patients intensifying OAD therapy, highlighting the unmet need for alternative treatment strategies in this population.

There are several limitations to this study. General limitations of observational, non-randomized studies include selection bias and the inability to confirm efficacy in the absence of a placebo arm. Nonetheless, real-world data do provide important insights, as discussed above. In this study, our data confirm that initiation of either medication (BI or GLP-1 RA) is considered only after attempts have been made to optimize the use of OADs for at least 6 months. While the large sample size is a strength of the study, the fact that it included primarily the hospital-
based cohort is a limitation; patients who were not part of the participating facilities were not captured in this study. The database consists of a limited number of hospitals and clinics and does not cover all regions of Japan. Furthermore, patients who transferred to other institutions could not be followed up, and data were based on prescriptions written; imperfect adherence could have reduced the effects of treatment. Persistence data are not currently available from this study to enable investigation of this aspect of treatment. The study was originally designed to compare outcomes between patients who received BI or GLP-1 RA but not the other, versus those who received sequential therapy with BI and GLP-1 RA. However, because of the low number of patients in the database with records of sequential therapy, only the cohort of patients initiating BI or GLP-1 RA without sequential therapy was analyzed. Additionally, the treatment options for GLP-1 RAs in Japan were not constant throughout the study period; for example, lixisenatide was approved in 2013, and dulaglutide was approved in 2015. While a 10-year period was considered, this was not a longitudinal study and, although it would have been interesting to investigate how treatment changed over time as different agents became available or more widely used, this was outside the scope of this analysis. Although subgroup analyses were conducted according to potentially relevant patient factors, additional unknown confounders could exist and contribute to any differences between BI and GLP-1 RA cohorts.

CONCLUSIONS

This retrospective, observational study conducted in Japan demonstrated that in patients with T2D inadequately controlled on OADs, escalation to BI or GLP-1 RA therapy occurred after many years of disease, when HbA1c levels had risen far above target values, and often after inadequate response to multiple OADs. Patients who initiated GLP-1 RA therapy tended to be slightly younger and have higher BMI and lower HbA1c at baseline compared with those who initiated BI therapy. The conditional probability of reaching HbA1c < 7% with BI or GLP-1 RA declined over time, suggesting that treatment intensification should be considered for patients who do not achieve their glycemic goal in the first 6–12 months on BI or GLP-1 RA. In particular, patients with high baseline HbA1c (≥ 9%) or those on multiple OADs (≥ 3) may benefit from early treatment escalation, based on the low probability of achieving target HbA1c in these patient populations. Overall, these results highlight the need for new treatment strategies to allow more patients in Japan with T2D inadequately controlled on OADs to achieve early glycemic control.

ACKNOWLEDGEMENTS

The authors thank Shiro Hinotsu, the representative director of the Health, Clinic, and Education Information Evaluation Institute, for database development for the study and Asuka Ozaki (Sanofi) for advice on data interpretation and critical review of the manuscript.

Funding. Sponsorship for this study and Rapid Service Fee were funded by Sanofi.

Medical Writing and Editorial Assistance. Editorial assistance in the preparation of this article was provided by Namiko Abe, PhD, of Caudex (New York, NY). Support for this assistance was funded by Sanofi.

Authorship. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis.

Prior Presentation. Interim data for this study were accepted for oral presentation at the 63rd Annual Meeting of the Japan Diabetes Society in February 2020 (abstract 91361). JDS 2020 was originally planned for May but is now scheduled in October.
Disclosures. Mike Baxter, Xuejun Victor Peng, and Robert Lubwama are employees of Sanofi. Yukiko Morimoto and Masami Tamiwa are employees of Sanofi K.K. Masakatsu Hattori is an employee of Real World Data Co., Ltd. Hiroshi Maegawa has received lecture fees from Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., Kissei Pharmaceutical Co., Ltd., Kowa Pharmaceutical Co. Ltd., Merck Sharp & Dohme, Mitsubishi Tanabe Pharma Corporation, Nippon Boehringer Ingelheim Co., Ltd., Novo Nordisk, Sanofi K.K., and Takeda Pharmaceutical Company Limited; and grants and research support from Astellas Pharma Inc., AstraZeneca K.K., Bayer Yakuhin, Ltd., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., Fuji Yakuhin Co., Ltd., Kowa Pharmaceutical Co. Ltd., Kyowa Hakko Kirin Co., Ltd., Merck Sharp & Dohme, Miki Corporation, Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Nitto Corp., Nissan Chemical Corporation, Novartis, Novo Nordisk, Ono Pharmaceutical Co., Ltd., Pfizer Japan Inc., Sanofi K.K., Sanwa Chemical Co., Ltd., Shionogi & Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Sunstar Inc., Teijin Pharma Limited, Taisho Toyama Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Company Limited.

Compliance with Ethics Guidelines. This study was approved by the Research Institute of Healthcare Data Science (RIHD) ethics committee (No. RI2019005). This article is based on an existing EMR database and does not contain any studies with human participants or animals.

Data Availability. These analyses were conducted on medical records data provided under a commercial license, which the authors are unable to share.

Open Access. This article is licensed under a Creative Commons Attribution-Non-Commercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES

1. Kahn SE, Cooper ME, Del PS. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 2014;383:1068–83.

2. Saisho Y. β-cell dysfunction: its critical role in prevention and management of type 2 diabetes. World J Diabetes. 2015;6:109–24.

3. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103–17.

4. [No authors listed]. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837–53.

5. Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41:2669–701.

6. Haneda M, Noda M, Origasa H, et al. Japanese clinical practice guideline for diabetes 2016. Diabetes Care. 2018;41:2669–701.

7. American Diabetes Association. Standards of medical care in diabetes–2020. Diabetes Care. 2020;43(Suppl 1):S1–S212.
8. Levin PA, Nguyen H, Wittbrodt ET, Kim SC. Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research. Diabetes Metab Syndr Obes. 2017;10:123–39.

9. Madenidou AV, Paschos P, Karagiannis T, et al. Comparative benefits and harms of basal insulin analogues for type 2 diabetes: a systematic review and network meta-analysis. Ann Intern Med. 2018;169:165–74.

10. Porcellati F, Lin J, Lucidi P, Bolli GB, Fanelli CG. Impact of patient and treatment characteristics on glycemic control and hypoglycemia in patients with type 2 diabetes initiated to insulin glargine or NPH: a post hoc, pooled, patient-level analysis of 6 randomized controlled trials. Medicine (Baltimore). 2017;96:e6022.

11. Singh S, Wright EE Jr, Kwan AY, et al. Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab. 2017;19:1347–58.

12. Blonde L, Meneghini L, Peng XV, et al. Probability of achieving glycemic control with basal insulin in patients with type 2 diabetes in real-world practice in the USA. Diabetes Ther. 2018;9:1347–58.

13. Peng XV, Blonde L, Shepherd L, Lubwama R, Ji L, McCrimmon RJ. A real-world retrospective study evaluating glycemic control with glucagon-like peptide-1 receptor agonists or basal insulin in type 2 diabetes in the UK. Diabetologia. 2019;62(Suppl 1):864.

14. STROBE. STrengthening the Reporting of OBservational studies in Epidemiology 2014. Available from: https://www.strobe-statement.org/index.php?id=strobe-home. Accessed 6 Nov 2019.

15. Kobayashi M, Tsukube S, Ikeda Y, Shuto Y. Safety and efficacy of combination therapy with insulin glargine and oral hypoglycaemic agents including DPP-4 inhibitors in Japanese T2DM patients: ALOHA 2 study, a post-marketing surveillance for Lantus®. J Diabetes Mellitus. 2014;4:273–89.

16. Satoh J, Andersen M, Bekker Hansen B, et al. Clinical inertia in basal insulin-treated patients with type 2 diabetes—results from a retrospective database study in Japan (JDDM 43). PLoS ONE. 2018;13:e0198160.

17. Ishii H, Iwamoto Y, Tajima N. An exploration of barriers to insulin initiation for physicians in Japan: findings from the Diabetes Attitudes, Wishes And Needs (DAWN) JAPAN study. PLoS ONE. 2012;7:e36361.

18. Morita Y, Murayama H, Odawara M, Bauer M. Treatment patterns of drug-naive patients with type 2 diabetes mellitus: a retrospective cohort study using a Japanese hospital database. Diabetol Metab Syndr. 2019;11:90.

19. Terauchi Y, Koyama M, Cheng X, et al. Glycaemic control and hypoglycaemia with insulin glargine 300 U/ml compared with glargine 100 U/ml in Japanese adults with type 2 diabetes using basal insulin plus oral anti-hyperglycaemic drugs (EDITION JP 2 randomised 12-month trial including 6-month extension). Diabetes Metab. 2017;43:446–52.

20. Onishi Y, Iwamoto Y, Yoo SJ, Clauson P, Tamer SC, Park S. Insulin degludec compared with insulin glargine in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, pan-Asian, treat-to-target trial. J Diabetes Investig. 2013;4:605–12.

21. Araki E, Inagaki N, Tanizawa Y, Oura T, Takeuchi M, Imaoka T. Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study. Diabetes Obes Metab. 2015;17:994–1002.

22. Inagaki N, Ueki K, Yamamura A, Saito H, Imaoka T. Long-term safety and efficacy of exenatide twice daily in Japanese patients with suboptimally controlled type 2 diabetes. J Diabetes Investig. 2011;2:448–56.

23. Inagaki N, Atsumi Y, Oura T, Saito H, Imaoka T. Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label,平行-group, multicenter, noninferiority study. Clin Ther. 2012;34:1892–908.

24. Kaku K, Kiyosue A, Ono Y, et al. Liraglutide is effective and well tolerated in combination with an oral antidiabetic drug in Japanese patients with type 2 diabetes: a randomized, 52-week, open-label, parallel-group trial. J Diabetes Investig. 2016;7:76–84.

25. Kaku K, Yamada Y, Watada H, et al. Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: a randomized trial. Diabetes Obes Metab. 2018;20:1202–12.
26. Seino Y, Terauchi Y, Wang X, Watanabe D, Niemeyer E, Study Investigators. Safety, tolerability and efficacy of lixisenatide as monotherapy in Japanese patients with type 2 diabetes mellitus: an open-label, multicenter study. J Diabetes Investig. 2018;9:108–18.

27. Edelman SV, Polonsky WH. Type 2 diabetes in the real world: the elusive nature of glycemic control. Diabetes Care. 2017;40:1425–32.